bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-05 |
2024-09 |
-0.38 |
N/A |
N/A |
N/A |
2024-09-13 |
2023-12 |
0 |
-0.78 |
N/A |
N/A |
2023-11-07 |
2023-09 |
-0.69 |
-0.66 |
0.03 |
4.35% |
2023-08-08 |
2023-06 |
-0.72 |
-0.67 |
0.05 |
6.94% |
2023-05-09 |
2023-03 |
-0.54 |
0.21 |
0.75 |
138.89% |
2023-03-29 |
2022-12 |
-0.45 |
0.38 |
0.83 |
184.44% |
Date |
Firm |
Action |
From |
To |
2023-10-16 |
Cantor Fitzgerald |
Upgrade |
|
Neutral |
2023-09-05 |
HSBC |
Upgrade |
|
Buy |
2023-07-18 |
B of A Securities |
Upgrade |
Neutral |
Buy |
2023-07-10 |
Morgan Stanley |
Upgrade |
Underweight |
Underweight |
2023-05-31 |
Barclays |
Upgrade |
Equal-Weight |
Overweight |
2023-04-27 |
JP Morgan |
Upgrade |
|
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2023-06-15 |
AGWUNOBI JOHN O |
Director |
26.46K |
Stock Award(Grant) |
2024-02-29 |
COLVIN RICHARD A |
Officer |
118.37K |
Sale |
2024-06-02 |
KLIMA THOMAS J |
Chief Operating Officer |
121.01K |
Sale |
2023-12-05 |
KRAWTSCHUK CHRISTOPHER CPA |
Chief Financial Officer |
45.47K |
Sale |
2023-06-15 |
LEIDERMAN ELISABETH M.D. |
Director |
22.26K |
Stock Award(Grant) |
2023-06-15 |
LESCHLY NICK |
Director |
459.64K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
State Street Corporation |
16.36M |
53.82M |
15.29% |
2023-06-29 |
Blackrock Inc. |
8.79M |
28.93M |
8.22% |
2023-06-29 |
Tang Capital Management, LLC |
7.38M |
24.29M |
6.90% |
2023-06-29 |
Pfm Health Sciences, Lp |
7.29M |
23.97M |
6.81% |
2023-06-29 |
Vanguard Group Inc |
5.57M |
18.33M |
5.21% |
2023-06-29 |
Granahan Investment Management LLC |
4.86M |
15.98M |
4.54% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF |
13.88M |
52.34M |
12.98% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.39M |
11.15M |
3.17% |
2023-08-30 |
iShares Russell 2000 ETF |
2.48M |
9.36M |
2.32% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.48M |
4.86M |
1.38% |
2023-09-29 |
Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh |
1.32M |
4.00M |
1.23% |
2023-08-30 |
iShares Russell 2000 Value ETF |
987.26K |
3.72M |
0.92% |
Split |
Date |
1544 : 1000 |
2021-11-05 |